[EN] PRMT5 INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5
申请人:MERCK SHARP & DOHME
公开号:WO2021126728A1
公开(公告)日:2021-06-24
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
Efficient and Scalable Synthesis of 3,4-Dihydroisoquinolin-1(2H)-ones by Benzylic Oxidation of Tetrahydroisoquinoline Derivatives using Cerium Ammonium Nitrate (CAN)
作者:Jiajun Luo、Zhilong Li、Jiaxin He、Tong Li、Daochen Wu、Yang Lai、Haiying Sun
DOI:10.1039/d4ob00491d
日期:——
tetrahydroisoquinoline derivatives using a catalytic amount of ceriumammoniumnitrate (CAN) and a stoichiometric amount of NaBrO3 as oxidants was developed. The reaction is significantly influenced by the substituent groups on the phenyl ring. While electron-withdrawing groups on the phenyl ring can lower the reactivities of the substrates, electron-donating groups on the phenyl ring can dramatically promote
开发了一种高效且可扩展的方法,通过使用催化量的硝酸铈铵 (CAN) 和化学计量的 NaBrO 3作为氧化剂,通过四氢异喹啉衍生物的苄基氧化来合成 3,4-二氢异喹啉-1( 2 H )-酮。该反应受苯环上的取代基的显着影响。虽然苯环上的吸电子基团可以降低底物的反应活性,但苯环上的给电子基团可以显着促进氧化速率。
EGFR INHIBITORS AND USES THEREOF
申请人:[en]DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
公开号:WO2024046221A1
公开(公告)日:2024-03-07
Disclosed herein are compounds or pharmaceutically acceptable salts thereof that are useful as EGFR inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions to treat EGFR-related disorder (e.g., cancers).